GlassScriptPhysician profile
Michele Carbonell-Smith
NPI 1447557160
$13,290.25
in general payments reported to CMS, 2019-2025
35 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,252 · 2022: $2,287 · 2023: $2,926 · 2024: $2,879 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,652 · Education: $98.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,652.44 |
| Education | $98.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,001.38 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,743.04 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,349.90 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $778.94 | 2021-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $636.41 | 2021-2025 | Dupixent |
| Genzyme Corporation | $588.61 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $556.13 | 2021-2025 | Uptravi, Opsumit |
| Electromed, INC. | $512.22 | 2021-2025 | Smartvest |
| Grifols USA, LLC | $465.18 | 2021-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $439.26 | 2021-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $432.46 | 2022-2025 | Tezspire, Tavneos |
| Mallinckrodt Hospital Products INC. | $315.58 | 2021-2023 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $308.64 | 2021-2025 | Cuvitru |
| Mylan Specialty L.P. | $295.86 | 2021-2024 | Yupelri |
| Verona Pharma, INC. | $246.02 | 2025 | Ohtuvayre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $204.18 | 2025 | Yupelri |
| Pulmonx Corporation | $188.14 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Merck Sharp & Dohme LLC | $179.33 | 2023-2025 | Keytruda, Zerbaxa, Recarbrio |
| Philips North America LLC | $139.18 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy, Reusable Vest |
| Inspire Medical Systems, INC. | $133.35 | 2024-2025 | Inspire |
| Genentech USA, INC. | $113.94 | 2022-2024 | Xolair |
| Axsome Therapeutics, INC. | $106.39 | 2024 | Auvelity |
| Baxter Healthcare | $99.36 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $66.24 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $64.20 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $62.42 | 2023 | |
| Vifor Pharma, INC. | $57.93 | 2024 | Zemaira |
| Lilly USA, LLC | $45.40 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $38.97 | 2024 | Wegovy |
| Mayne Pharma Commercial LLC | $32.79 | 2021 | |
| Ambu INC. | $25.02 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.30 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2025 | |
| Phadia US INC. | $14.99 | 2021 | |
| Liquidia Technologies, INC. | $13.53 | 2025 | Yutrepia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Carbonell-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.